



Dear Physician,

Adverse outcomes of chronic kidney disease (CKD) can often be prevented or delayed through early detection and treatment. According to the National Kidney Foundation (NKF), the estimated glomerular filtration rate (eGFR) is the most effective method to determine if a person has CKD. eGFR is based on a person's serum creatinine, age, gender, and race.

CIGNA is requesting that LabCorp automatically include the eGFR on lab reports for its participants when a serum creatinine has been requested and the age and gender is provided. The eGFR calculation will only apply to patients 18 years and older and will provide a result for both African and non-African Americans. The inclusion of the eGFR will not increase the cost of the lab test. We hope you find this information helpful.

Among patients with chronic kidney disease, the stage of disease should be assigned based on the level of kidney function, irrespective of diagnosis, according to the NKF's Kidney Disease Outcomes Quality Initiative (K/DOQI) CKD classification:

Stage	eGFR (mL/min/1.73m <sup>2</sup> )
Stage 1 Kidney damage with normal GFR	= or > 90
Stage 2 Kidney damage with mild decrease in GFR	60 - 89
Stage 3 Kidney damage with moderate decrease in GFR	30 - 59
Stage 4 Kidney damage with severe decrease in GFR	15 - 29
Stage 5 Kidney failure	< 15

According to the NKF KDOQI guidelines, patients with CKD should be referred to a specialist for consultation and co-management if the clinical action plan cannot be prepared, the prescribed evaluation of the patient cannot be carried out, or the recommended treatment cannot be carried out. In general, patients with GFR < 30 mL/min/1.73m<sup>2</sup> should be referred to a nephrologist, however, patients with eGFR results between 30 and 60 mL/min/1.73m<sup>2</sup> should be evaluated for the presence of urine microalbumin and other risk factors associated with CKD such as hypertension and diabetes.

Please see the attached link for the complete version of the KDOQI Guidelines:

<http://www.kidney.org/professionals/KDOQI/guidelines>

Sincerely,

Dick Salmon, MD/PhD  
Senior National Medical Director  
CIGNA HealthCare

*"CIGNA" is a registered service mark, licensed for use by operating subsidiaries of CIGNA Corporation. Products and services are provided exclusively by operating subsidiaries, including Connecticut General Life Insurance Company, and not by CIGNA Corporation.*